Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Uveal Melanoma 1 Recurrence 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Leukemia, Myelomonocytic, Chronic 1 Hodgkin Disease 1 Hematologic Neoplasms 1 Graft vs Host Disease 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 17 fludarabine 13 Dexamethasone 12 Cisplatin 12 Rituximab 10 Gemcitabine 9 Paclitaxel 8 Bendamustine Hydrochloride 8 Lenalidomide 7 Decitabine 7 Cytarabine 7 Carboplatin 7 fludarabine phosphate 6 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6 Etoposide 6 Bortezomib 6 Radiotherapy 5 Injections 5 Azacitidine 5 camrelizumab 4 apatinib 4 Valproic Acid 4 Thalidomide 4 Procarbazine 4 Oxaliplatin 4 Drug Therapy 4 Bevacizumab 4 Antilymphocyte Serum 4 venetoclax 3 pomalidomide 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Recurrence × treosulfan × Clear all

NCT01010243 2012-05-30

MM03

University of Regensburg

Phase 1/2 Unknown

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡